We attempted to determine which monoamine receptor subtypes are predominantly involved in antidepressant-induced antinociception. Antinociceptive effects were evaluated by using formalin tests with rats. Antidepressants acting as potent inhibitors of norepinephrine reuptake (nisoxetine, nortriptyline, and maprotiline) or inhibiting reuptake of both norepinephrine and serotonin (5-HT) (imipramine and milnacipran) induced dose-dependent antinociception. Simultaneous intraperitoneal administration of antidepressants and either prazosin (␣ 1 antagonist) or ketanserin (5-HT 2 antagonist) significantly antagonized antinociceptive effects. Fluvoxamine (selective serotonin reuptake inhibitor) induced antinociception less potently than other antidepressants and was significantly antagonized by ketanserin, but not prazosin. Ondansetron (5-HT 3 antagonist) significantly antagonized antinociception by 10 mg/kg of imipramine. In contrast, SDZ-205,557 (5-HT 4 antagonist) markedly enhanced antinociception by small-dose (2.5 mg/kg) imipramine. Imipramine-induced antinociception was significantly antagonized by intracerebroventricular administration of prazosin or ketanserin, but not by yohimbine (␣ 2 antagonist) or ondansetron, and was significantly enhanced by intracerebroventricularly administered SDZ-205,557. These findings suggest that ␣ 1 adrenoceptors and 5-HT 2 receptors in the brain are involved in antidepressant-induced antinociception. In addition, the results suggested functional interactions between noradrenergic and serotonergic neurons as mechanisms for antidepressantinduced antinociception. (Anesth Analg 2002;95:163-8) A ntidepressants have antinociceptive effects in addition to antidepressant activity (1-3). Although thorough comparisons of the antinociceptive potencies of clinically used antidepressants have not been conducted, our previous study (with formalin tests in rats) suggested that classic tricyclic antidepressants exert more potent antinociceptive effects than selective serotonin reuptake inhibitors (SSRIs) (4).
We attempted to determine which monoamine receptor subtypes are predominantly involved in antidepressant-induced antinociception. Antinociceptive effects were evaluated by using formalin tests with rats. Antidepressants acting as potent inhibitors of norepinephrine reuptake (nisoxetine, nortriptyline, and maprotiline) or inhibiting reuptake of both norepinephrine and serotonin (5-HT) (imipramine and milnacipran) induced dose-dependent antinociception. Simultaneous intraperitoneal administration of antidepressants and either prazosin (␣ 1 antagonist) or ketanserin (5-HT 2 antagonist) significantly antagonized antinociceptive effects. Fluvoxamine (selective serotonin reuptake inhibitor) induced antinociception less potently than other antidepressants and was significantly antagonized by ketanserin, but not prazosin. Ondansetron antagonist) significantly antagonized antinociception by 10 mg/kg of imipramine. In contrast, SDZ-205,557 (5-HT 4 antagonist) markedly enhanced antinociception by small-dose (2.5 mg/kg) imipramine. Imipramine-induced antinociception was significantly antagonized by intracerebroventricular administration of prazosin or ketanserin, but not by yohimbine (␣ 2 antagonist) or ondansetron, and was significantly enhanced by intracerebroventricularly administered SDZ-205,557. These findings suggest that ␣ 1 adrenoceptors and 5-HT 2 receptors in the brain are involved in antidepressant-induced antinociception. In addition, the results suggested functional interactions between noradrenergic and serotonergic neurons as mechanisms for antidepressantinduced antinociception.
(Anesth Analg 2002;95:163-8)
A ntidepressants have antinociceptive effects in addition to antidepressant activity (1) (2) (3) . Although thorough comparisons of the antinociceptive potencies of clinically used antidepressants have not been conducted, our previous study (with formalin tests in rats) suggested that classic tricyclic antidepressants exert more potent antinociceptive effects than selective serotonin reuptake inhibitors (SSRIs) (4) .
The neurochemical mechanisms of antinociceptive effects of antidepressants have not been well described. Most antidepressants inhibit the reuptake of monoamines, including norepinephrine and serotonin (5-HT), at neuronal terminals (5) . Increased levels of monoamines in synaptic clefts are therefore presumed to lead to changes in pain thresholds and induce antinociception. However, there is still controversy over the identity of the monoamine receptors (or receptor subtypes) responsible for these analgesic effects, in addition to their location (central or peripheral) (6, 7) .
Thus, in this study, by using the formalin test in rats, we attempted to determine the identity and possible localization of the monoamine receptor subtypes (␣ 1,2 and 5-HT 2,3,4 ) predominantly involved in the antinociceptive effects of antidepressants, by investigating antagonism of antidepressant-induced antinociception after peripheral or central administration of specific receptor antagonists. In addition, we propose a possible mechanism for interactions between the noradrenergic and serotonergic systems involved in antidepressant-induced antinociception.
Methods
We used 380 male Wistar rats (Japan SLC, Hamamatsu, Japan) weighing 180 to 245 g. The rats were housed in groups of four to six animals at 20°C to 24°C, in a humidity-controlled room under a 12:12-h light/dark cycle (lights on at 6:00 am and off at 6:00 pm). The rats were supplied food and water ad libitum and were given at least 3 days to adapt to the animal room before being tested. The ambient temperature during testing was 20°C to 24°C. The animals were brought to the test room at least 1 h before testing. Each rat was used for only one experiment. All procedures were in strict accordance with the National Institutes of Health's guidelines for the care and use of laboratory animals and were approved by our Animal Care and Use Committee.
The antinociceptive effects of antidepressants were evaluated by using formalin tests in rats. Sixty minutes before formalin injection, animals were intraperitoneally (IP) administered an antidepressant (2 mL/ kg) with or without simultaneous administration of a monoamine receptor antagonist. Fifty microliters of formalin solution (2% in water) was injected subcutaneously into the plantar surface of the right hind paw with a 27-gauge needle. The animal was then immediately placed into an open Plexiglas box (30 ϫ 30 ϫ 34 cm) serving as the observation chamber. Rats usually lick the injected paw in two phases: immediately after injection (early phase) and approximately 20 min after injection (late phase). We measured the total time (in seconds) that the animal spent licking the injected paw during the period lasting from 10 to 30 min after formalin injection (late phase).
Each rat was gently placed into the center of a Plexiglas box (30 ϫ 30 ϫ 34 cm) 60 min after IP administration of an antidepressant. The number of line crossings (lines dividing the floor into nine parts) was then counted for 15 min and used as ambulatory locomotor activity data.
Two days before the experiment, the animal was anesthetized with an IP administration of pentobarbital sodium (50 mg/kg) and placed onto a stereotaxic instrument (Narishige Scientific Instrument Laboratory, Tokyo, Japan). Stainless-steel 27-gauge guide cannulae were then aseptically implanted in bilateral hemispheres of the cerebral cortex. The lower tip of each cannula was positioned 2.0 mm from the center of each lateral ventricle (distance from the bregma: anterior, Ϫ1.0 mm; lateral, Ϯ1.5 mm; vertical, ϩ2.0 mm) (8) . On the day of the experiment, 60 min before the formalin injection, animals underwent IP administration of an antidepressant, and injection needles (outer diameter, 0.2 mm; inner diameter, 0.08 mm) were inserted through the guide cannulae into both lateral ventricles (2.0 mm beyond the guide cannula) 40 min after antidepressant administration. A monoamine receptor antagonist or saline (control) was administered into both lateral ventricles at a rate of 1.0 L/min for 5 min (total volume for both ventricles, 10 L) through the injection needles by using a microsyringe pump (EP-60; EICOM, Tokyo, Japan). After the injection needles were removed, the formalin test was performed as described previously. Accurate placement of the cannulae was visually confirmed after the experiment by checking the diffusion of blue ink injected into the ventricles.
The following antidepressants were used: nortriptyline HCl, nisoxetine HCl, maprotiline HCl, and imipramine HCl (Sigma, St. Louis, MO); milnacipran HCl (donated by Asahikasei Corp., Osaka, Japan); fluvoxamine maleate (donated by Solvay Pharmaceutical, Weesp, The Netherlands); and citalopram HBr (donated by Zeria Pharmaceutical, Tokyo, Japan). The following selective ␣-adrenergic or serotonergic receptor antagonists were used: prazosin HCl and yohimbine HCl (Sigma); ketanserin tartrate (RBI, Natick, MA); ondansetron HCl (donated by Glaxo Wellcome, Tokyo, Japan); and SDZ-205,557 (RBI). The dosages of all antagonists used in this study were chosen to selectively block a corresponding receptor, on the basis of data from published in vivo studies (9 -11) . We randomized the assignments of drugs and dosages among the rats.
Results are expressed as mean Ϯ sem. The statistical significance of differences between experimental data was analyzed with analysis of variance, followed by the Sheffé post hoc test. Values of P Ͻ 0.05 were considered indicative of statistical significance. Table 1 shows the results of formalin tests for the antinociceptive effects of antidepressants. All the SSRIs (nortriptyline, nisoxetine, and maprotiline) and the drugs inhibiting both norepinephrine and 5-HT reuptake (imipramine and milnacipran) produced significant dose-dependent reductions in the time spent by the rats licking the injected paw. Antinociceptive effects were observed for nisoxetine at doses larger than 2.5 mg/kg; for nortriptyline, imipramine, and milnacipran at doses larger than 5 mg/kg; and for maprotiline at doses larger than 10 mg/kg. At 20 mg/ kg, nortriptyline, nisoxetine, and imipramine nearly abolished the formalin-induced nociceptive response (86.3%, 96.2%, and 95.1% reduction of licking time, respectively).
Results
In the open field test, apparent inhibition of ambulatory activity was not observed after IP administration of nortriptyline (5 mg/kg), nisoxetine (2.5 mg/ kg), maprotiline (10 mg/kg), imipramine (5 mg/kg), milnacipran (5 mg/kg), or fluvoxamine (20 mg/kg). These are the minimal doses that induce significant differences in formalin-induced nociception (data not shown). Figure 1A shows the effects of the ␣ 1 -receptor antagonist prazosin and the 5-HT 2 antagonist ketanserin on antinociception induced by the selective norepinephrine reuptake inhibitors nortriptyline (5 mg/kg), nisoxetine (2.5 mg/kg), and maprotiline (10 mg/kg), as indicated by the formalin test. Pretreatment with prazosin (1 mg/kg) and ketanserin (1 mg/kg) significantly and almost completely antagonized the suppression of licking time. Licking time was increased by the following amounts: nortriptyline, from 60.6 to 136.6 and 137.0 s; nisoxetine, from 54.8 to 153.0 and 119.2 s; and maprotiline, from 59.1 to 122.9 and 148.4 s for prazosin and ketanserin, respectively. Figure 1B shows the effects of pretreatment with prazosin and ketanserin on the antinociception induced by the 5-HT and norepinephrine reuptake inhibitor milnacipran ( 
Discussion
This study and previous studies (4) demonstrated that antidepressants selectively inhibiting reuptake of norepinephrine only (nortriptyline, nisoxetine, and maprotiline) or 5-HT only (SSRIs; fluvoxamine and citalopram) or inhibiting the reuptake of both norepinephrine and 5-HT (imipramine and milnacipran) could all induce antinociception. SSRIs demonstrated this effect to a lesser extent than other antidepressants. Antidepressants increase monoamine levels in synaptic clefts by inhibiting the reuptake of monoamines into nerve terminals, resulting in increased stimulation of monoamine receptors. It has thus been assumed that certain subtypes of monoamine receptors are involved in antidepressantinduced antinociception. The antinociceptive potency of selective inhibitors of norepinephrine reuptake was greatest in nisoxetine, followed by nortriptyline and maprotiline. This seems to be comparable with reported in vitro K i values for the inhibition of norepinephrine uptake (1.3, 4.0, and 7.4 nM, respectively) (5). These findings are likely to support the involvement of stimulation of monoamine receptors in antidepressant-induced antinociception. In contrast to our study, Jourdan et al. (12) have reported that nortriptyline did not significantly affect the pain score during formalin tests in rats. The reasons for the discrepancy between their findings and ours are not clear. However, the large concentration of formalin (5%) used in their study compared with that in ours (2%) might have elicited pain too intense to be antagonized by nortriptyline.
The antinociceptive effects of nortriptyline, nisoxetine, maprotiline, and milnacipran (in this study) and of imipramine (4) are significantly and markedly antagonized by the ␣ 1 antagonist prazosin and the 5-HT 2 antagonist ketanserin. In the previous study (4), the selective ␣ 1A antagonist WB-4101 also significantly inhibited imipramine-induced antinociception, supporting the possibility of ␣ 1 -receptor involvement in antinociception by antidepressants. In addition, the antinociceptive effects of imipramine in this study were markedly antagonized by the 5-HT 3 antagonist ondansetron. In contrast, the 5-HT 4 antagonist SDZ-205,557 induced significant antinociception, but only when coadministered with a small dose of imipramine. These results suggest that the ␣ 1 adrenoceptors and the 5-HT 2 and 5-HT 3 receptors are involved in the antinociception induced by antidepressants and that stimulation of the 5-HT 4 receptors antagonizes or buffers this antinociception ( Table 2) . Stimulation of the 5-HT 4 receptors might be one of reasons why SSRIs demonstrate less antinociceptive activity than classic antidepressants. In our previous study using the same experimental method as this study, we found that the antinociceptive effects of imipramine during the formalin test in rats were not significantly affected by either the IP-administered ␣ 2 antagonist yohimbine or the 5-HT 1A antagonist WAY-100,635 (4). This suggests that participation of the ␣ 2 adrenoceptors and the 5-HT 1A receptors in antidepressant-induced antinociception either is not obvious or is less dominant than that of the ␣ 1 adrenoceptors and the 5-HT 2 and 5-HT 3 receptors (Table 2) .
Several previous reports support our findings regarding the contributions of monoamine receptors to antidepressant-induced antinociception. Ansuategui et al. (13) found that the antinociceptive effects of clomipramine were closely related to ␣ 1 adrenoceptors, but not ␣ 2 adrenoceptors. Walker et al. (14) reported that the 5-HT 2 antagonists pirenperone and ritanserin reduced naloxone-induced antinociception. It has also been demonstrated that ondansetron attenuates the antinociceptive effect of nifedipine, an L-type calcium channel blocker, in rats (10) and that SDZ-205,557 antagonizes visceral and cutaneous pain in mice (11) .
However, in contrast to our findings, some articles have indicated that either 5-HT 1A or 5-HT 3 receptors are involved in 5-HT-induced pain (15, 16) . In addition, clonidine, an ␣ 2 agonist, is effective in relieving neuropathic and cancer pain (17, 18) . The reasons for the discrepancies between our findings and these studies are unclear. One possible explanation is that the involvement of these monoamine receptor subtypes in the regulation of pain under conditions in which monoamine levels in synaptic clefts have been markedly increased by antidepressants is different from that under normal, stable conditions in the absence of antidepressants. However, Ghelardini et al. (19) and Sahebgharani and Zarrindast (20) reported that ␣ 2 adrenoceptors were likely to be involved in antidepressant-dependent antinociception in mice. The discrepancy between their findings and ours might be partly attributable to differences in experimental conditions, such as the quality of the noxious stimulus and the species (the formalin test in rats in our study versus the hot-plate test and the writhing test in mice in their studies).
Because IP-administered antagonists can block monoamine receptors in both the central nervous system and local peripheral regions, we were unable to localize the receptors involved in antidepressantinduced antinociception. Therefore, we instead investigated the involvement of receptors in the brain in the antinociceptive effects of imipramine, by using ICV administration of antagonists. The antinociceptive effects of imipramine were significantly antagonized by prazosin and ketanserin but were not affected by yohimbine or ondansetron. In contrast, the antinociceptive effects of imipramine were significantly and markedly enhanced by SDZ-205,557. These findings suggest that the ␣ 1 adrenoceptors and the 5-HT 2 and 5-HT 4 receptors, which are involved in the antinociceptive effects of imipramine, are at least partially localized in the brain (Table 2 ). This conclusion is supported by findings indicating that ICV pretreatment with prazosin prevents the induction of antinociception by ICV administration of norepinephrine (21) and that ICV pretreatment with ketanserin inhibits antinociception induced by calcitonin (22) . Asano et al. (23) also suggested that ␣ 1 adrenoceptors may participate in pain control at the supraspinal level. In this study, IP administration of ondansetron significantly antagonized the antinociception induced by imipramine, but ICV administration of ondansetron did not. However, the involvement of central 5-HT 3 receptors in the antinociceptive effect of imipramine could not be excluded; concentrations of the antagonist might not reach effective levels at the site of action of imipramine in the brain, because of dilution. Bardin et al. (24) reported that intrathecal pretreatment with the 5-HT 3 antagonist tropisetron reversed the antinociception induced by intrathecally administered 5-HT. Thus, further experiments are needed to determine whether central 5-HT 3 receptors might contribute to the antinociceptive effect of antidepressants. In this investigation, the antinociceptive effects of antidepressants that selectively inhibit norepinephrine reuptake (nortriptyline, nisoxetine, and maprotiline) were significantly and markedly antagonized by 5-HT 2 antagonists. This suggests that, in antidepressant-related antinociception, noradrenergic neurons interact with serotonergic neurons. In addition, the antinociceptive effects of the SSRI fluvoxamine in this study were antagonized by the 5-HT 2 antagonist but were not affected by the ␣ 1 antagonist. From these findings, we speculated possible neuronal interactions at the supraspinal level, in which noradrenergic neurons innervate serotonergic neurons presynaptically and presynaptic ␣ 1 receptors stimulate 5-HT secretion. Plaznik et al. (25) suggested a functional interaction between noradrenergic and serotonergic systems in rats and demonstrated that norepinephrine released from noradrenergic terminals in the median raphe nucleus regulates the activity of 5-HT. However, morphological evidence for interactions among noradrenergic neurons, serotonergic neurons, and 5-HT receptor subtypes has not yet been adequately demonstrated. Further pharmacological and anatomical investigations are therefore necessary to elucidate the mechanisms involved in antidepressant-induced antinociception.
